| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID6129: Hepatocellular carcinoma (unresectable, untreated) - tislelizumab |
|
Medicine details |
|
| Medicine name | tislelizumab |
| Formulation | intravenous infusion |
| Reference number | 3883 |
| Indication | First-line treatment of advanced hepatocellular carcinoma (HCC) |
| Company | Novartis Oncology |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/03/2023 |
| NICE guidance | ID6129: Hepatocellular carcinoma (unresectable, untreated) - tislelizumab |